Related references
Note: Only part of the references are listed.Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience
Ashley Rose et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
PD-1 blockade for untreated Hodgkin lymphoma
Alison J. Moskowitz
BLOOD (2021)
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
Victor M. Orellana-Noia et al.
BLOOD ADVANCES (2021)
Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era
Kekoa Taparra et al.
LEUKEMIA & LYMPHOMA (2020)
Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma
Theodore S. Thomas et al.
JOURNAL OF GERIATRIC ONCOLOGY (2020)
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J. Broeckelmann et al.
JAMA ONCOLOGY (2020)
How I treat nodular lymphocyte-predominant Hodgkin lymphoma
Dennis A. Eichenauer et al.
BLOOD (2020)
Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors
Santosha Vardhana et al.
ONCOLOGIST (2019)
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand et al.
BLOOD (2019)
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma
Marc Sorigue et al.
LEUKEMIA & LYMPHOMA (2019)
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
Ann S. LaCasce
HEMATOLOGICAL ONCOLOGY (2019)
Management of older Hodgkin lymphoma patients
Andrew M. Evens et al.
Hematology-American Society of Hematology Education Program (2019)
Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
Anja Mottok et al.
BLOOD (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
Alison J. Moskowitz
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty
Ralph M. Meyer
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms
Manli Jiang et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
Hodgkin Lymphoma Outcome: A Retrospective Study from 3 Tertiary Centers in Saudi Arabia
Ruaa G. Shafi et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
The role of screening and monitoring for bleomycin pulmonary toxicity
Brittney M. Shippee et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era
Azim Jalali et al.
ANNALS OF HEMATOLOGY (2016)
Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Boell et al.
BLOOD (2016)
PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher
Pamela Blair Allen et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era
Qin Wang et al.
ONCOTARGET (2016)
Outcome of patients older than 60years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly
Aspasia Stamatoullas et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy
Kazuho Miyashita et al.
LEUKEMIA RESEARCH (2015)
Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity
Adam Jona et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy
Yuki Nakajima et al.
MEDICAL ONCOLOGY (2014)
Revisiting bleomycin from pathophysiology to safe clinical use
Marios Froudarakis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
Andrew M. Evens et al.
BLOOD (2012)
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned
Simonetta Viviani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
beta 2-Microglobulin: emerging as a promising cancer therapeutic target
Chunmeng Shi et al.
DRUG DISCOVERY TODAY (2009)
Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study
Massimo Federico et al.
HAEMATOLOGICA (2007)
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial
DB Duggan et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
